Document:

EX-10.5

 Exhibit 10.5 
 ARATANA THERAPEUTICS, INC. 
 EMPLOYMENT AGREEMENT 

This EMPLOYMENT AGREEMENT (this “Agreement”) is made and
entered into as of September 17, 2012 by and between ARATANA THERAPEUTICS, INC. (the “Company”) and Louise Mawhinney (the “Executive”). The
Company and the Executive are hereinafter collectively referred to as the “Parties”, and individually referred to as a “Party”. 
 RECITALS 
 A. The Company desires to employ the
Executive to serve as its Chief Financial Officer, subject to the terms and conditions set forth in this Agreement, effective as of September 25, 2012 (such date being referred to herein as the “Effective Date”). 

B. The Executive desires to accept such employment by the Company, subject to the terms and conditions set forth in this
Agreement, effective as of the Effective Date. 
 AGREEMENT 

In consideration of the foregoing Recitals and the mutual promises and covenants herein contained, and for other good and valuable
consideration, the Parties, intending to be legally bound, agree as follows: 
 1. EMPLOYMENT. 

1.1 Offer and Acceptance of Employment. The Company hereby agrees to employ the Executive, and the Executive hereby accepts such
employment with the Company, in each case effective as of the Effective Date and otherwise subject to the terms and conditions set forth in this Agreement. 
 1.2 Title. Effective as of the Effective Date, the Executive’s position shall be designated as Chief Financial Officer, subject to the terms and conditions set forth in this Agreement.

 1.3 Term. The term of this Agreement shall begin on the Effective Date and shall continue until terminated pursuant to
Section 4 herein (the “Term”); provided, however, that the Parties expressly acknowledge and agree that the Executive’s employment with the Company is at will and may, subject to the provisions of
Section 4, be terminated by the Company or by the Executive at any time for any reason or for no reason. 
 1.4
Duties. During the Term, the Executive shall perform such services as are normally associated with the position of Chief Financial Officer and shall report to the Company’s President and Chief Executive Officer. 

1.5 Policies and Practices. The employment relationship between the Parties shall be governed by this Agreement and by the
policies and practices established by the Company and the Company’s board of directors (the “Board”). In the event that the terms of this Agreement differ from or are in conflict with the Company’s policies or
practices as in effect from time to time, this Agreement shall control. 
 1.6 Location. Unless the Parties otherwise
agree in writing, during the Term the Executive shall perform the services the Executive is required to perform pursuant to this Agreement at a business office established by the Company following the date of this Agreement that is located within
fifty (50) miles of the Executive’s residence on the Effective Date as set forth on the signature page hereto; provided, however, that the Company may from time to time require the Executive to travel temporarily to other
locations (including Kansas City) in connection with the Company’s business; and provided further that the Executive may elect in her sole discretion to perform the services the Executive is required to perform pursuant to this
Agreement at any other business office established by the Company (including in Kansas City). 

 2. LOYAL AND CONSCIENTIOUS
PERFORMANCE; NONCOMPETITION. 
 2.1 Loyalty. During the Executive’s employment by
the Company, the Executive shall devote the Executive’s full business energies, interest, abilities and productive time to the proper and efficient performance of the Executive’s duties under this Agreement; provided,
however, that, subject to Section 2.2 and Section 2.3 and provided that such activities do not materially interfere with the performance of the Executive’s duties under this Agreement, the Executive may participate in the
activities listed on Exhibit A attached hereto, as well as charitable, community or civic activities, and any other activities that may be disclosed by the Executive in writing in advance to, and approved by, the Board after the date
hereof. 
 2.2 Covenant Not to Compete. The Executive acknowledges and agrees that the business of the Company is
nationwide in scope. The Executive further acknowledges and agrees that during the course of her employment with the Company she will learn confidential information relating to the Company and its business and business strategies and will develop
business relationships on behalf of the Company at the Company’s expense. The Executive acknowledges and agrees that if she were to divert this information and the relationships to a competitor, the Company would suffer irreparable harm to its
business and goodwill in an amount that cannot be readily quantified. Accordingly, the Executive agrees that during the Term and for six (6) months following the termination of her employment for any reason, the Executive shall not engage in
competition with the Company and/or any of its Affiliates (as defined below), either directly or indirectly, in any manner or capacity, as adviser, principal, agent, Affiliate, promoter, partner, officer, director, employee, stockholder, owner,
co-owner, consultant or member of any association or otherwise, in any phase of the business of developing, licensing, manufacturing, distributing or marketing of products or services that are in the same Field of Use (as defined below) or which are
otherwise in competition with the actual or reasonably anticipated products or services of the Company at the time of her separation from the Company, except with the prior written consent of the Board. For purposes of this Agreement,
“Field of Use” means the development of companion animal therapeutic products. The Executive acknowledges and agrees that because of the nationwide scope of the Company’s business, this restriction shall be nationwide.
For purposes of this Agreement, “Affiliate” means, with respect to any specific entity, any other entity that, directly or indirectly, through one or more intermediaries, controls, is controlled by or is under common control
with such specified entity. Ownership by the Executive in professionally managed funds over which the Executive 

  
 2 

 
does not have control or discretion in investment decisions or as a passive investment of less than two percent (2%) of the outstanding shares of capital stock of any corporation with one or
more classes of its capital stock listed on a national securities exchange or publicly traded on a national securities exchange or in the over-the-counter market shall not constitute a breach of this Section 2.2. 

2.3 Covenant Not To Solicit. The Executive agrees that during the Term and for one (1) year following the termination of her
employment for any reason, she shall not, directly or indirectly, solicit or recruit any employees of the Company to terminate their work for the Company or to perform services in competition with the Company. 

2.4 Acknowledgement Regarding Indemnification. The Company and the Executive expressly acknowledge and agree that the Executive
shall, at all times during the Term of this Agreement, be deemed to be and qualify as an “executive officer” for purposes of Article XI of the Company’s bylaws as in effect as of the Effective Date and shall be entitled to
all of the rights and remedies relating to the indemnification of executive officers of the Company pursuant thereto. 
 3.
COMPENSATION OF THE EXECUTIVE. 
 3.1 Base Salary. The
Company shall pay the Executive a base salary at the rate of Two Hundred Seventy-Five Thousand U.S. Dollars ($275,000.00) per year (the “Base Salary”), less payroll deductions and all required withholdings, payable in
regular periodic payments in accordance with the Company’s normal payroll practices. The Base Salary shall be prorated for any partial year of employment on the basis of a 365-day fiscal year. The Base Salary shall be subject to review and
adjustment from time to time by and at the sole discretion of the Board or any committee thereof. 
 3.2 Annual Bonus.
The Executive will be eligible to receive an annual cash bonus (the “Bonus”) payment of up to thirty percent (30%) of the Base Salary with respect to each calendar year, subject to the Executive’s continued
employment with the Company as of the end of such calendar year and contingent upon successful achievement of corporate objectives established from year to year by the Board. Any Bonus pursuant to this Section 3.2 shall be paid as promptly as
practicable following the end of the applicable calendar year, but not later than March 15th of the following calendar year. 
 3.3 Equity Compensation. 
 3.3.1 Stock Option. 

(i) Subject to Board approval, promptly following the Effective Date, the Company shall grant the Executive an incentive stock
option (the “Stock Option”) pursuant to the Company’s 2010 Equity Incentive Plan (the “Plan”) to purchase up to that number of shares of the Company’s common stock (the “Common
Stock”) as is equal to 0.67% of all shares of Common Stock that are: (x) outstanding; (y) issuable upon conversion of outstanding convertible securities or upon exercise of outstanding options and warrants; or
(z) reserved for issuance pursuant to the Plan (after giving effect to an increase in the number of shares of Common Stock reserved for issuance pursuant to the Plan that is sufficient to allow for

  
 3 

 
the grant of all Equity Compensation (as defined below) to be granted under this Agreement) (the “Fully Diluted CSEs”) on the date of grant, at the Common Stock’s
fair market value as determined in good faith by the Board as of the date of such grant. 
 (ii) The Stock Option shall
be granted subject to the terms and conditions of the Plan and a written option agreement to be entered into by the Company and the Executive (the “Option Agreement”). The Option Agreement shall provide, among other things,
that the shares of Common Stock underlying the Stock Option (the “Option Shares”) shall vest: (x) as to 1/4th of the Option Shares, upon the first (1st) anniversary of the date of grant of the Stock Option; and
(y) as to the remaining Option Shares, in equal monthly installments over the next thirty-six (36) months such that all shares shall be vested as of the fourth (4th) anniversary of the date of grant of the Stock Option, subject to the
Executive’s continued employment with the Company on each such vesting date; provided, however, that: (a) the Stock Option shall be subject to accelerated vesting as provided in Section 3.3.3, Section 4.5.1 and
Section 4.5.3(iii); and (b) “early exercise” of the Stock Option shall be permitted pursuant to the terms of the Plan and the Option Agreement. 
 3.3.2 Restricted Stock Award. 
 (i) Subject to Board
approval, promptly following the Effective Date, the Company shall grant the Executive, without payment of additional consideration by the Executive, an award of restricted stock (the “Restricted Stock Award” and, together
with the Stock Option, the “Equity Compensation”) pursuant to the Plan for that number of shares of Common Stock as is equal to 0.33% of the Company’s Fully Diluted CSEs on the date of grant. 

(ii) The Restricted Stock Award shall be granted subject to the terms and conditions of the Plan and a written award agreement to
be entered into by the Company and the Executive (the “Restricted Stock Award Agreement”). The Restricted Stock Award Agreement shall provide, among other things, that all shares of Common Stock underlying the Restricted
Stock Award (the “Restricted Shares”) shall vest: (x) as to 1/4th of the Restricted Shares, upon the first (1st) anniversary of the date of grant of the Restricted Stock Award; and (y) as to the remaining
Restricted Shares, in equal monthly installments over the next thirty-six (36) months such that all shares shall be vested as of the fourth (4th) anniversary of the date of grant of the Restricted Stock Award, subject to the
Executive’s continued employment with the Company on each such vesting date; provided, however, that the Restricted Stock Award shall be subject to accelerated vesting as provided in Section 3.3.3, Section 4.5.1 and
Section 4.5.3(iii). 
 3.3.3 Double-Trigger Acceleration. In the event that the Executive’s employment with
the Company is terminated by the Company (or its successor) without Cause (as defined below) or by the Executive for Good Reason (as defined below) on account of or within twelve (12) months following the date of the consummation of a Change in
Control (as defined below) (such period, the “Double-Trigger Period”), the vesting and exercisability of each of the Executive’s outstanding stock awards (including any stock options, restricted stock or other awards
granted to the Executive by the Company) shall be automatically accelerated in full. 

  
 4 

 3.4 Expense Reimbursements. The Company will reimburse the Executive for all
reasonable business expenses the Executive incurs in conducting her duties hereunder, pursuant to the Company’s usual expense reimbursement policies, provided that the Executive supplies the appropriate substantiation for such expenses. Any
amounts payable under this Section 3.4 shall be made in accordance with Treasury Regulation Section 1.409A-3(i)(1)(iv) and shall be paid on or before the last day of the Executive’s taxable year following the taxable year in which the
Executive incurred the expenses. The amounts provided under this Section 3.4 during any taxable year of the Executive’s will not affect such amounts provided in any other taxable year of the Executive’s, and the Executive’s right
to reimbursement for such amounts shall not be subject to liquidation or exchange for any other benefit. 
 3.5 Employment
Taxes. All of the Executive’s compensation shall be subject to all applicable federal, state and local taxes and withholdings, as well as any others that the Company determines it is legally required to withhold. 

3.6 Benefits; Vacation. The Executive shall, in accordance with Company policy and the terms of the applicable plan documents, be
eligible to participate in benefits under any benefit plan or arrangement that may be in effect from time to time and made available to the Company’s senior management employees, including with respect to additional coverage for spouses,
domestic partners and eligible dependents. In addition to the foregoing, the Executive shall be entitled to three (3) weeks’ paid vacation time per year, subject to a maximum accrual of three (3) weeks. 

4. TERMINATION. 
 4.1 Termination by the Company. The Executive’s employment with the Company is at will and may be terminated by the Company at any time and for any reason, or for no reason, including, but not
limited to, under the following conditions: 
 4.1.1 Termination by the Company for Cause. The Company may terminate the
Executive’s employment under this Agreement for Cause by delivery of written notice to the Executive specifying the Cause or Causes relied upon for such termination. Any notice of termination given pursuant to this Section 4.1.1 shall
effect termination as of the date of the notice, or as of such other date as specified in the notice. 
 4.1.2 Termination
by the Company Without Cause. The Company may terminate the Executive’s employment under this Agreement without Cause at any time and for any reason, or for no reason, by delivery of written notice to the Executive. Any notice of
termination given pursuant to this Section 4.1.2 shall effect the termination of the Executive’s employment hereunder as of the date of such notice, or as of such other date as is specified in such notice. 

4.2 Termination by the Executive. The Executive’s employment with the Company is at will and may be terminated by the
Executive at any time and for any reason, or for no reason, including, but not limited to, under the following conditions: 

4.2.1 Termination by the Executive for Good Reason. The Executive may terminate her employment under this Agreement for Good
Reason in accordance with the procedures specified in Section 4.6.2 below. 
 4.2.2 Termination by the Executive
Without Good Reason. The Executive may terminate her employment under this Agreement for other than Good Reason at any time. 

  
 5 

 4.3 Termination for Death or Complete Disability. The Executive’s employment
with the Company shall automatically terminate effective upon the date of the Executive’s death or Complete Disability (as defined below). 
 4.4 Termination by Mutual Agreement of the Parties. The Executive’s employment with the Company may be terminated at any time upon a written mutual agreement of the Parties. Any such
termination of employment shall have the consequences specified in such agreement. 
 4.5 Compensation Upon Termination.

 4.5.1 Death or Complete Disability. If the Executive’s employment shall be terminated by death or Complete
Disability as provided in Section 4.3, the Company shall pay to the Executive, or to the Executive’s heirs, as applicable, the Base Salary and accrued and unused vacation benefits earned through the date of termination at the rate in
effect at the time of termination, plus all other amounts to which the Executive is entitled under any compensation plan or practice of the Company at the time of termination, less standard deductions and withholdings. In addition, the vesting
and/or exercisability of each of the Executive’s outstanding stock awards (including any stock options, restricted stock or other awards granted to the Executive by the Company) shall be automatically accelerated on the date of termination as
to the number of stock awards that would have vested over the twelve (12) month period following the date of termination had the Executive remained continuously employed by the Company during such period. The Company shall thereafter have no
further obligations to the Executive and/or to the Executive’s heirs under this Agreement, except as otherwise provided by law. 
 4.5.2 With Cause or Without Good Reason. If the Executive’s employment is terminated by the Company for Cause, or if the Executive terminates her employment hereunder without Good Reason, the
Company shall pay to the Executive the Base Salary and accrued and unused vacation benefits earned through the date of termination at the rate in effect at the time of termination, plus all other amounts to which the Executive is entitled under any
compensation plan or practice of the Company at the time of termination, less standard deductions and withholdings. The Company shall thereafter have no further obligations to the Executive under this Agreement, except as otherwise provided by law.

 4.5.3 Without Cause or for Good Reason. If the Company terminates the Executive’s employment without Cause or
the Executive terminates her employment hereunder for Good Reason, the Company shall pay to the Executive the Base Salary and accrued and unused vacation benefits earned through the date of termination at the rate in effect

  
 6 

 
at the time of termination, plus all other amounts to which the Executive is entitled under any compensation plan or practice of the Company at the time of termination, less standard deductions
and withholdings. In addition, subject to the Executive’s: (i) furnishing to the Company an executed waiver and release of claims in substantially the form attached hereto as Exhibit B (which form may be amended to comply with
legal requirements arising after the Effective Date) (the “Release”) no later than forty-five (45) days following the Executive’s termination; and (ii) allowing the Release to become effective in accordance
with its terms, the Executive shall be entitled to the following: 
 (i) an amount equal to fifty percent (50%) of
the Base Salary in effect at the time of termination (but determined prior to any reduction in the Base Salary that would give rise to the Executive’s right to voluntarily resign for Good Reason pursuant to Section 4.6.2), less standard
deductions and withholdings, paid in equal installments over a period of six (6) months pursuant to the Company’s standard payroll practices (the “Cash Severance”); 

(ii) should the Executive elect to continue Company-sponsored group health insurance benefits in accordance with the provisions
of COBRA or State Continuation, as applicable, following the date of termination, to the extent that doing so will not result in adverse tax consequences or violate applicable law, the Company shall pay the full premium for such group health
insurance continuation benefits for the Executive and any eligible dependents for a period of six (6) months after the effective date of the Release; provided, however, that any such payments will cease if the Executive
voluntarily enrolls in a health insurance plan offered by another employer or entity during the period in which the Company is paying such premiums. The Executive agrees to promptly notify the Company in writing of any such enrollment. For purposes
of this Section 4.5.3(ii), references to COBRA or State Continuation premiums shall not include any amounts payable by the Executive under an Internal Revenue Code Section 125 health care reimbursement plan; and 

(iii) subject to the provisions of Section 3.3.3 during the Double-Trigger Period, the vesting and/or exercisability of each
of the Executive’s outstanding stock awards (including any stock options, restricted stock or other awards granted to the Executive by the Company) shall be automatically accelerated on the date of termination as to the number of stock awards
that would have vested over the six (6) month period following the date of termination had the Executive remained continuously employed by the Company during such period. 
 4.6 Definitions. For purposes of this Agreement, the following terms shall have the following meanings: 
 4.6.1 Complete Disability. “Complete Disability” shall mean the inability of the Executive to perform the Executive’s duties under this Agreement, even with reasonable
accommodation, because the Executive has become permanently disabled within the meaning of any policy of long-term disability income insurance covering employees of the Company then in force. In the event the Company has no policy of disability
income insurance covering employees of the Company in force when the Executive becomes disabled, the term “Complete Disability” shall mean the inability of the Executive to perform the Executive’s duties

  
 7 

 
under this Agreement, even with reasonable accommodation, by reason of any incapacity, physical or mental, which the Board, based upon medical advice or an opinion provided by a licensed
physician mutually acceptable to the Board and the Executive, determines to have incapacitated the Executive from satisfactorily performing all of the Executive’s usual services for the Company, even with reasonable accommodation, for a period
of at least one hundred twenty (120) days during any twelve (12) month period (whether or not consecutive). Based upon such medical advice or opinion, the determination of the Board shall be final and binding and the date such
determination is made shall be the date of such Complete Disability for purposes of this Agreement. 
 4.6.2 Good
Reason. “Good Reason” for the Executive to terminate her employment hereunder shall mean the occurrence of any of the following events without the Executive’s consent: 

(i) a material diminution in the Executive’s authority, duties or responsibilities relative to her authority, duties or
responsibilities in effect immediately prior to such reduction; 
 (ii) a material change in the geographic location at
which the Executive must perform her duties to a point that is located more than fifty (50) miles from the Executive’s residence as set forth on the signature page hereto or, in the event that the Executive elects to perform the services
required by this Agreement at any other business office established by the Company, a material change in the geographic location at which the Executive must perform her duties to a point that is located more than fifty (50) miles from such
business office; 
 (iii) a material diminution by the Company of the Executive’s base compensation as initially
set forth herein or as the same may be increased from time to time; or 
 (iv) any other action or inaction that
constitutes a material breach by the Company or any successor or Affiliate of its obligations to the Executive under this Agreement; provided, however, that such termination by the Executive shall only be deemed for Good Reason
pursuant to the foregoing definition if: (x) the Executive gives the Company written notice of the intent to terminate for Good Reason within thirty (30) days following the first occurrence of the condition(s) that the Executive believes
constitutes Good Reason, which notice shall describe such condition(s); (y) the Company fails to remedy such condition(s) within thirty (30) days following receipt of the written notice (the “Cure Period”); and
(z) the Executive terminates her employment within thirty (30) days following the end of the Cure Period. 
 4.6.3
Cause. “Cause” for the Company to terminate the Executive’s employment hereunder shall mean the occurrence of any of the following events, as determined by the Board or a committee designated by the Board, in its
sole discretion: 
 (i) the Executive’s conviction of any felony or any crime involving moral turpitude or
dishonesty; 
 (ii) the Executive’s participation in a fraud involving or against the Company; 

  
 8 

 (iii) the Executive’s willful and material breach of the Executive’s
duties hereunder that is not cured within thirty (30) days after the Executive’s receipt of written notice from the Board of such breach; 
 (iv) the Executive’s intentional and material damage to the Company’s property; or 
 (v) the Executive’s material breach of the Non-Disclosure and Assignment Agreement (as defined below); 
 provided, however, that prior to the determination that Cause under this Section 4.6.3 has occurred, the Company shall: (w) provide to the Executive in writing, in reasonable
detail, the reasons for the determination that such Cause exists; (x) other than with respect to clause (iii) above which specifies the applicable period of time for the Executive to remedy her breach, afford the Executive a reasonable
opportunity to remedy any such breach; (y) provide the Executive an opportunity to be heard prior to the final decision to terminate the Executive’s employment hereunder for such Cause; and (z) make any decision that such Cause exists
in good faith. 
 4.6.4 Change in Control. “Change in Control” shall mean the occurrence, in a
single transaction or in a series of related transactions, of any one or more of the following events: (i) there is consummated a merger, consolidation or similar transaction involving (directly or indirectly) the Company if, immediately after
the consummation of such merger, consolidation or similar transaction, the stockholders of the Company immediately prior thereto do not own, directly or indirectly, either (a) outstanding voting securities representing more than fifty percent
(50%) of the combined outstanding voting power of the surviving entity in such merger, consolidation or similar transaction or (b) more than fifty percent (50%) of the combined outstanding voting power of the parent of the surviving
entity in such merger, consolidation or similar transaction; (ii) the stockholders of the Company approve or the Board approves a plan of complete dissolution or liquidation of the Company, or a complete dissolution or liquidation of the
Company shall otherwise occur; or (iii) there is consummated a sale of all or substantially all of the consolidated assets of the Company and its subsidiaries, other than a sale of all or substantially all of the consolidated assets of the
Company and its subsidiaries to an entity more than fifty percent (50%) of the combined voting power of the voting securities of which entity is owned by stockholders of the Company in substantially the same proportion as their ownership of the
Company immediately prior to such sale; provided, however, that the term “Change in Control” shall not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the
Company. 
 4.7 Survival of Certain Sections. Sections 2.2, 2.3, 2.4, 4, 5, 6, 7, 8, 9, 12, 13, 16 and 18 of this
Agreement will survive the termination of this Agreement. 
 4.8 Parachute Payment. If any payment or benefit the
Executive would receive pursuant to this Agreement (each, a “Payment”) would: (i) constitute a “Parachute Payment” within the meaning of Section 280G of the Internal Revenue Code of 1986, as amended
(the “Code”); and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then such Payment shall be reduced to the

  
 9 

 
Reduced Amount. The “Reduced Amount” shall be equal to the largest portion of the Payment (including all of it) which, after taking into account all applicable federal,
state and local income and employment taxes (all computed at the highest applicable marginal rate), and the Excise Tax, if applicable, results in the Executive’s receipt, on an after-tax basis, of the greatest amount of the Payment, whether or
not all or some portion of the Payment is subject to the Excise Tax. If a reduction in payments or benefits constituting Parachute Payments is necessary so that the Payment equals the Reduced Amount, reduction shall occur in the following order
unless the Executive elects in writing a different order (provided, however, that such election shall be subject to Company approval if made on or after the effective date of the event that triggers the Payment): reduction of cash
payments; cancellation of accelerated vesting of stock awards; reduction of employee benefits. In the event that acceleration of vesting of stock award compensation is to be reduced, such acceleration of vesting shall be cancelled in the reverse
order of the date of grant of the Executive’s stock awards unless the Executive elects in writing a different order for cancellation. Notwithstanding anything to the contrary set forth herein, the Executive may not elect the order in which the
reduction in the Executive’s payments or benefits will occur if such election would cause any such amounts to constitute “nonqualified deferred compensation” within the meaning of Section 409A of the Code such that the Executive
would incur the additional twenty percent (20%) tax under Section 409A of the Code (the “409A Tax”). In addition, if a different order of reduction is required to avoid the 409A Tax, that order shall apply.

 The accounting firm then engaged by the Company for general audit purposes shall perform the foregoing calculations. The
Company shall bear all expenses with respect to the determinations by such accounting firm required to be made hereunder. 
 The
accounting firm engaged to make the determinations hereunder shall provide its calculations, together with detailed supporting documentation, to the Executive and the Company within fifteen (15) calendar days after the date on which the
Executive’s right to a Payment is triggered (if requested at that time by the Executive or the Company) or such other time as requested by the Executive or the Company. If the accounting firm determines that no Excise Tax is payable with
respect to a Payment, either before or after the application of the Reduced Amount, it shall furnish the Executive and the Company with an opinion reasonably acceptable to the Executive that no Excise Tax will be imposed with respect to such
Payment. Any good faith determinations of the accounting firm made hereunder shall be final, binding and conclusive upon the Executive and the Company. 
 4.9 Application of Internal Revenue Code Section 409A. Notwithstanding anything to the contrary set forth herein, any Cash Severance amounts that constitute “nonqualified deferred
compensation” within the meaning of Section 409A of the Code shall not commence in connection with the Executive’s termination of employment unless and until the Executive has also incurred a “separation from service” within
the meaning of Section 409A of the Code, unless the Company reasonably determines that such amounts may be provided to the Executive without causing the Executive to incur the 409A Tax. To the extent any Cash Severance amounts: (i) are
paid following the date of termination of the Executive’s employment through March 15 of the calendar year following such termination, such severance benefits are intended to constitute separate payments for purposes of
Section 1.409A-2(b)(2) of the Treasury Regulations and thus payable pursuant to the “short-term deferral” rule set forth in 

  
 10 

 
Section 1.409A-1(b)(4) of the Treasury Regulations; (ii) are paid following said March 15, such Cash Severance benefits are intended to constitute separate payments for purposes of
Section 1.409A-2(b)(2) of the Treasury Regulations made upon an involuntary separation from service and payable pursuant to Section 1.409A-1(b)(9)(iii) of the Treasury Regulations, to the maximum extent permitted by said provision; and
(iii) are in excess of the amounts specified in clauses (i) and (ii) of this paragraph, shall (unless otherwise exempt under Treasury Regulations) be considered separate payments subject to the distribution requirements of
Section 409A(a)(2)(A) of the Code, including, without limitation, the requirement of Section 409A(a)(2)(B)(i) of the Code that payments or benefits be delayed until six (6) months and one (1) day after the Executive’s
separation from service if the Executive is a “specified employee” within the meaning of the aforesaid section of the Code at the time of such separation from service. In the event that a six (6) month and one (1) day delay of
any such separation payments or benefits is required, on the first regularly scheduled pay date following the conclusion of the delay period the Executive shall receive a lump sum payment or benefit in an amount equal to the separation payments and
benefits that were so delayed, and any remaining separation payments or benefits shall be paid on the same basis and at the same time as otherwise specified pursuant to this Agreement (subject to applicable tax withholdings and deductions).

 5. CONFIDENTIAL AND PROPRIETARY
INFORMATION. As a condition of employment, the Executive agrees to execute and abide by the Company’s standard form of Non-Disclosure and Proprietary Rights Assignment Agreement (the “Non-Disclosure
and Assignment Agreement”). 
 6. ASSIGNMENT AND BINDING
EFFECT. This Agreement shall be binding upon and inure to the benefit of the Executive and the Executive’s heirs, executors, personal representatives, assigns, administrators and legal representatives. Because
of the unique and personal nature of the Executive’s duties under this Agreement, neither this Agreement nor any rights or obligations under this Agreement shall be assignable by the Executive. This Agreement shall be binding upon and inure to
the benefit of the Company and its successors, assigns and legal representatives. Any such successor of the Company will be deemed substituted for the Company under the terms of this Agreement for all purposes and the Company will require any
successor to all or substantially all of the business or assets of the Company expressly to assume and to agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such
succession had taken place. For this purpose, “successor” means any person, firm, corporation or other business entity which at any time, whether by purchase, merger or otherwise, directly or indirectly acquires all or substantially all of
the assets or business of the Company. 
 7. NOTICES. All notices or demands of any kind
required or permitted to be given by the Company or the Executive under this Agreement shall be given in writing and shall be personally delivered (and receipted for) or faxed during normal business hours or mailed by certified mail, return receipt
requested, postage prepaid, addressed as follows: 
 If to the Company: 

Aratana Therapeutics, Inc. 
 1901 Olathe Boulevard 
 Kansas City, KS 66103 

Attention: Chairman of the Board 
 If to the Executive, to the address set forth on the signature page hereto. 

  
 11 

 Any such written notice shall be deemed given on the earlier of the date on which such notice is personally
delivered or three (3) days after its deposit in the United States mail as specified above. Either Party may change its address for notices by giving notice to the other Party in the manner specified in this section. 

8. CHOICE OF LAW. This Agreement shall be construed and interpreted in
accordance with the internal laws of the State of Delaware. The Executive and the Company consent to non-exclusive personal jurisdiction in any state and, if otherwise permitted by law, federal court situated in the State of Delaware for the
resolution of all claims arising under this Agreement that are subject to resolution in court rather than through arbitration. 

9. INTEGRATION. This Agreement, including Exhibit A, together with the Non-Disclosure
and Assignment Agreement, contains the complete, final and exclusive agreement of the Parties relating to the terms and conditions of the Executive’s employment and the termination of the Executive’s employment, and supersedes all prior
oral and written employment agreements or arrangements between the Parties. 
 10.
AMENDMENT. This Agreement cannot be amended or modified except by a written agreement signed by the Executive and the Company. 
 11. WAIVER. No term, covenant or condition of this Agreement or any breach thereof shall be deemed waived, except with the written consent of the Party against whom
the wavier is claimed, and any waiver or any such term, covenant, condition or breach shall not be deemed to be a waiver of any preceding or succeeding breach of the same or any other term, covenant, condition or breach. 

12. SEVERABILITY. The finding by a court of competent jurisdiction of the unenforceability,
invalidity or illegality of any provision of this Agreement shall not render any other provision of this Agreement unenforceable, invalid or illegal. Such court shall have the authority to modify or replace the invalid or unenforceable term or
provision with a valid and enforceable term or provision, which most accurately represents the Parties’ intention with respect to the invalid or unenforceable term, or provision. 

13. INTERPRETATION; CONSTRUCTION. The headings set forth in this Agreement are for
convenience of reference only and shall not be used in interpreting this Agreement. This Agreement has been drafted by legal counsel representing the Company, but the Executive has been encouraged to consult with, and has consulted with, the
Executive’s own independent counsel and tax advisors with respect to the terms of this Agreement. The Parties acknowledge that each Party and its counsel has reviewed and revised, or had an opportunity to review and revise, this Agreement, and
any rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of this Agreement. 

  
 12 

 14. REPRESENTATIONS AND
WARRANTIES. The Executive represents and warrants that the Executive is not restricted or prohibited, contractually or otherwise, from entering into and performing each of the terms and covenants contained in this
Agreement, and that the Executive’s execution and performance of this Agreement will not violate or breach any other agreements between the Executive and any other person or entity. 

15. COUNTERPARTS. This Agreement may be executed in two (2) counterparts, each of which shall
be deemed an original, all of which together shall constitute one and the same instrument. 
 16.
ARBITRATION. To ensure the rapid and economical resolution of disputes that may arise in connection with the Executive’s employment with the Company, the Executive and the Company agree that any and all
disputes, claims, or causes of action, in law or equity, arising from or relating to the Executive’s employment, or the termination of that employment, will be resolved, to the fullest extent permitted by law, by final, binding and confidential
arbitration pursuant to the Federal Arbitration Act in Kansas City, Kansas conducted by the Judicial Arbitration and Mediation Services/Endispute, Inc. (“JAMS”), or its successors, under the then current rules of JAMS for
employment disputes; provided that the arbitrator shall: (a) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law; and (b) issue a written
arbitration decision including the arbitrator’s essential findings and conclusions and a statement of the award. ACCORDINGLY, THE EXECUTIVE AND THE COMPANY HEREBY IRREVOCABLY WAIVE ANY RIGHT TO A JURY TRIAL IN ANY LEGAL PROCEEDING ARISING OUT
OF OR RELATING TO THIS AGREEMENT. Both the Executive and the Company shall be entitled to all rights and remedies that either the Executive or the Company would be entitled to pursue in a court of law. The Company shall pay any JAMS filing fee and
shall pay the arbitrator’s fee. The arbitrator shall have the discretion to award attorneys’ fees to the party the arbitrator determines is the prevailing party in the arbitration; provided, however, that the prevailing party
shall be reimbursed for such fees, costs and expenses within sixty (60) days following any such award, but, to the extent the Executive is the prevailing party, in no event later than the last day of the Executive’s taxable year following
the taxable year in which the fees, costs and expenses were incurred; provided, further, that the Parties’ obligations pursuant to the provisos set forth above shall terminate on the tenth (10th) anniversary of the date of
the Executive’s termination of employment. Nothing in this Agreement is intended to prevent either the Executive or the Company from obtaining equitable relief in court to prevent irreparable harm pending the conclusion of any such arbitration.
Notwithstanding the foregoing, the Executive and the Company each have the right to resolve any issue or dispute involving a claim of misappropriation or infringement of confidential, proprietary or trade secret information, or intellectual property
rights, in any court of competent jurisdiction instead of via arbitration. 
 17. TRADE SECRETS
OF OTHERS. It is the understanding and intention of both the Company and the Executive that the Executive shall not divulge to the Company and/or its subsidiaries any confidential information or trade
secrets belonging to others, including the Executive’s former employers, nor shall the Company and/or its Affiliates seek to elicit from the 

  
 13 

 
Executive any such information. The Executive shall not provide to the Company and/or its Affiliates or use on their behalf any such information or any documents or copies of documents containing
such information. 
 18. ADVERTISING WAIVER. The Executive agrees to permit,
during and following the term of this Agreement, and without receiving additional compensation, the Company, and persons or other organizations authorized by the Company, to use, publish and distribute advertising or sales promotional literature
concerning the products and/or services of the Company, or the machinery and equipment used in the provision thereof, in which the Executive’s name and/or pictures of the Executive taken in the course of the Executive’s provision of
services to the Company appear. The Executive hereby waives and releases any claim or right the Executive may otherwise have arising out of such use, publication or distribution. 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  
 14 

 IN WITNESS WHEREOF, the
Parties have executed this agreement as of the date first written above. 
  

			
	ARATANA THERAPEUTICS, INC.
	
	 /s/ Steven St. Peter

	By:	 	Steven St. Peter
	Its:	 	President
		
	Dated:	 	9/12/2012

			
	
	EXECUTIVE:
	
	 /s/ Louise Mawhinney

	LOUISE MAWHINNEY
	
	Dated: 9/13/2012
		
	Address:	 	22 Frost Lane
		 	Sudbury, MA 01776

 [SIGNATURE PAGE TO EMPLOYMENT AGREEMENT] 

 EXHIBIT A 

PERMITTED ACTIVITIES 
  

	1)	Paratek Pharmaceuticals, Inc. 

  

	 	•	 	 Intends to join the Board of Directors following the date of this Agreement 

  
 16 

 EXHIBIT B 

RELEASE AND WAIVER OF CLAIMS 
 TO BE SIGNED FOLLOWING TERMINATION WITHOUT CAUSE 
 OR RESIGNATION FOR GOOD
REASON 
 In consideration of the payments and other benefits set forth in the Employment Agreement dated September 17,
2012 (the “Employment Agreement”), to which this form is attached, I, Louise Mawhinney, hereby furnish ARATANA THERAPEUTICS, INC. (the
“Company”), with the following release and waiver (“Release and Waiver”). 
 In
exchange for the consideration provided to me by Section 4 of the Employment Agreement that I am not otherwise entitled to receive, I hereby generally and completely release the Company and its directors, officers, employees, shareholders,
partners, agents, attorneys, predecessors, successors, parent and subsidiary entities, insurers, Affiliates, and assigns from any and all claims, liabilities and obligations, both known and unknown, that arise out of or are in any way related to
events, acts, conduct, or omissions occurring prior to my signing this Release and Waiver, except claims that the law does not permit me to waive by signing this Release and Waiver. This general release includes, but is not limited to: (1) all
claims arising out of or in any way related to my employment with the Company or the termination of that employment; (2) all claims related to my compensation or benefits from the Company, including salary, bonuses, commissions, vacation pay,
expense reimbursements, severance pay, fringe benefits, stock, stock options, or any other ownership interests in the Company; (3) all claims for breach of contract, wrongful termination, and breach of the implied covenant of good faith and
fair dealing; (4) all tort claims, including claims for fraud, defamation, emotional distress, and discharge in violation of public policy; and (5) all federal, state, and local statutory claims, including claims for discrimination,
harassment, retaliation, attorneys’ fees, or other claims arising under the federal Civil Rights Act of 1964 (as amended), the federal Americans with Disabilities Act of 1990, the federal Age Discrimination in Employment Act of 1967 (as
amended) (“ADEA”), the Kansas Anti-discrimination Act and the Kansas Age Discrimination in Employment Act. 
 Notwithstanding the foregoing, nothing in this Release and Waiver shall constitute a release by me of any claims or damages based on any right I may have to enforce the Company’s executory
obligations under the Employment Agreement, or my eligibility for indemnification under applicable law, Company governance documents or under any applicable insurance policy with respect to my liability as an employee or officer of the Company, or
my rights pursuant to my stock awards (including any stock options, restricted stock or other awards granted to me by the Company) pursuant to their terms. 
 I acknowledge that, among other rights, I am waiving and releasing any rights I may have under ADEA, that this Release and Waiver is knowing and voluntary, and that the consideration given for this
Release and Waiver is in addition to anything of value to which I was already entitled as an executive of the Company. If I am 40 years of age or older upon execution of this Release and Waiver, I further acknowledge that I have been advised,
as required by the Older Workers Benefit Protection Act, that: (a) the release and waiver granted herein does not relate to 

  
 17 

 
claims under the ADEA which may arise after this Release and Waiver is executed; (b) I should consult with an attorney prior to executing this Release and Waiver; (c) I have twenty-one
(21) days from the date of termination of my employment with the Company in which to consider this Release and Waiver (although I may choose voluntarily to execute this Release and Waiver earlier); (d) I have seven (7) days following
the execution of this Release and Waiver to revoke my consent to this Release and Waiver; and (e) this Release and Waiver shall not be effective until the seven (7) day revocation period has expired. 

I acknowledge my continuing obligations under my Non-Disclosure and Assignment Agreement. Pursuant to the Non-Disclosure and Assignment
Agreement I understand that among other things, I must not use or disclose any confidential or proprietary information of the Company and I must promptly return all Company property and documents (including all embodiments of proprietary
information) and all copies thereof in my possession or control. I understand and agree that my right to severance pay I am receiving in exchange for my agreement to the terms of this Release and Waiver is contingent upon my continued compliance
with my Non-Disclosure and Assignment Agreement. 
 This Release and Waiver constitutes the complete, final and exclusive
embodiment of the entire agreement between the Company and me with regard to the subject matter hereof. I am not relying on any promise or representation by the Company that is not expressly stated herein. This Release and Waiver may only be
modified by a writing signed by both me and a duly authorized officer of the Company. 
  

									
	Date:	 	  
	 		 	By:	 	  

					
		 		 		 	Name:	 	  

  
 18 

 ARATANA THERAPEUTICS, INC. 

AMENDMENT NO. 1 TO 
 EMPLOYMENT AGREEMENT 
 THIS AMENDMENT
NO. 1 TO EMPLOYMENT AGREEMENT (this “Amendment”) is made and entered into as of April 29, 2013, by and between ARATANA
THERAPEUTICS, INC., a Delaware corporation (the “Company”), and Louise Mawhinney (the “Executive”). Capitalized terms used and not otherwise defined herein
shall have the meanings given to them in the Original Agreement (as defined below). 
 RECITALS 

WHEREAS, the Company and the Executive are parties to that certain Employment Agreement, dated as of
September 17, 2012 (the “Original Agreement”); and 
 WHEREAS, in accordance
with Section 10 of the Original Agreement, the Company and the Executive desire to amend the Original Agreement as set forth in this Amendment. 
 NOW, THEREFORE, in consideration of the mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of
which are hereby acknowledged, the parties agree as follows: 
 AMENDMENT 

1. AMENDMENTS TO ORIGINAL AGREEMENT. 

1.1 Amendment to Section 3.3.1. Section 3.3.1 of the Original Agreement is hereby retitled “Stock
Options” and is hereby amended by adding the following subparagraphs (iii) and (iv) following existing subparagraph (ii): 
 “(iii) On the date the Company’s registration statement relating to its initial public offering becomes effective (the “IPO Effective Date”), the Company shall grant the
Executive a stock option (the “IPO Stock Option”) pursuant to the Company’s 2013 Incentive Award Plan or such other equity incentive plan or similar plan in effect on the IPO Effective Date (the “New
Plan”) to purchase 25,000 shares of Common Stock (adjusted for any stock splits, reverse stock splits or other changes affecting the shares of Common Stock that may occur prior to the date of grant), at a per share exercise price equal
to the fair market value of a share of Common Stock on the date of grant. 
 (iv) The IPO Stock Option shall be
granted subject to the terms and conditions of the New Plan and a written option agreement to be entered into by the Company and the Executive (the “IPO Option Agreement”). The IPO Option Agreement shall provide, among other
things, that the shares of Common Stock underlying the IPO Stock Option (the “IPO Option Shares”) shall vest: (x) as to 1/4th of the IPO Option 

 
Shares, upon the first (1st) anniversary of the date of grant of the IPO Stock Option; and (y) as to the remaining IPO Option Shares, in equal monthly installments over the next
thirty-six (36) months such that all shares shall be vested as of the fourth (4th) anniversary of the date of grant of the IPO Stock Option, subject to the Executive’s continued employment with the Company on each such vesting date;
provided, however, that: (a) the IPO Stock Option shall be subject to accelerated vesting as provided in Section 4.5.1 and Section 4.5.3(iii); and (b) “early exercise” of the IPO Stock Option shall be
permitted pursuant to the terms of the New Plan and the IPO Option Agreement.” 
 1.2 Amendment to Section 3.3.
Section 3.3.3 is hereby deleted in its entirety. 
 1.3 Amendment to Section 4.5.3. Subparagraphs (i),
(ii) and (iii) of Section 4.5.3 of the Original Agreement are hereby amended and restated in their entirety to read as follows: 
 “(i) payment in an amount equal to fifty percent (50%) of the Executive’s annual Base Salary in effect at the time of termination (or 100% of the Executive’s Base Salary in effect at
the time of termination, in the event the termination occurs on account of or within twelve (12) months following the date of the consummation of a Change in Control (as defined below) (such period, the “Double-Trigger
Period”)) (with the amount of the Base Salary determined prior to any reduction in the Base Salary that would give rise to the Executive’s right to voluntarily resign for Good Reason pursuant to Section 4.6.2), less standard
deductions and withholdings, paid in equal installments over a period of six (6) months (or twelve (12) months, in the event the termination occurs during the Double-Trigger Period) pursuant to the Company’s standard payroll practices
(the “Cash Severance”); 
 (ii) should the Executive elect to continue Company-sponsored
group health insurance benefits in accordance with the provisions of COBRA or State Continuation, as applicable, following the date of termination, to the extent that doing so will not result in adverse tax consequences or violate applicable law,
the Company shall pay the full premium for such group health insurance continuation benefits for the Executive and any eligible dependents for a period of six (6) months (or twelve (12) months, in the event the termination occurs during
the Double-Trigger Period) after the effective date of the Release; provided, however, that any such payments will cease if the Executive voluntarily enrolls in a health insurance plan offered by another employer or entity during the
period in which the Company is paying such premiums. The Executive agrees to promptly notify the Company in writing of any such enrollment. For purposes of this Section 4.5.3(ii), references to COBRA or State Continuation premiums shall not
include any amounts payable by the Executive under an Internal Revenue Code Section 125 health care reimbursement plan; and 

  
 2 

 (iii) the vesting and/or exercisability of each of the Executive’s
outstanding stock awards (including any stock options, restricted stock or other awards granted to the Executive by the Company) shall be automatically accelerated on the effective date of the Release as to the number of stock awards that would have
vested over the six (6) month period following the date of termination had the Executive remained continuously employed by the Company during such period; provided, however, that in the event that the termination occurs during the
Double-Trigger Period, the vesting and exercisability of each of the Executive’s outstanding stock awards shall be automatically accelerated in full, which shall mean at target for any portion of an award that vests based on the achievement of
performance goals.” 
 2. MISCELLANEOUS 

2.1 Effective Date. This Amendment shall become effective on the IPO Effective Date, if and only if the following conditions (the
“Conditions”) are satisfied: (i) the Executive is still employed by the Company on the IPO Effective Date, and (ii) the IPO Effective Date is no later than September 30, 2013. For the avoidance of doubt, if
either of the Conditions is not satisfied, this Amendment shall be of no force or effect and shall not become effective. 

2.2 No Other Amendment. Except as specifically amended by this Amendment, the terms and conditions of the Original Agreement shall
remain unchanged and in full force and effect. 
 2.3 Counterparts; Execution by Facsimile. This Amendment may be
executed in any number of counterparts, each of which shall be deemed an original and all of which together shall constitute one and the same instrument. The exchange of copies of this Amendment and of signature pages thereto by facsimile
transmission or by e-mail transmission in portable digital format, or similar format, shall constitute effective execution and delivery of such instrument(s) by the parties and may be used in lieu of the original Amendment for all purposes.

 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  
 3 

 IN WITNESS WHEREOF, the
parties have duly executed and delivered this AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT as of the date first written above. 

COMPANY: 
  

			
	ARATANA THERAPEUTICS, INC.
		
	By:	 	/s/ Steven St. Peter
	Name: Steven St. Peter
	Its:      President and CEO

			
		
	Dated:  	 	4/29/2013

 EXECUTIVE: 

			
	
	/s/ Louise Mawhinney

 LOUISE MAWHINNEY 

 

			
		
	Dated:  	 	4/29/2013

 [SIGNATURE PAGE TO AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT]EX-10.6

 Exhibit 10.6 
 ARATANA THERAPEUTICS, INC. EMPLOYMENT AGREEMENT 
 This EMPLOYMENT
AGREEMENT (this “Agreement”) is made and entered into as of September 6, 2012 (the “Effective Date”) by and between ARATANA THERAPEUTICS, INC. (the “Company”)
and Linda Rhodes (the “Executive”). The Company and the Executive are hereinafter collectively referred to as the “Parties”, and individually referred to as a “Party”.

 RECITALS 
 A. As of the date of this Agreement, the Executive is employed by the Company pursuant to the terms of that certain Employment Agreement, dated as of December 27, 2010, by and between the
Company and the Executive, as amended by that certain Amendment No. 1 to Employment Agreement, dated as of November 1, 2011, by and between the Company and the Executive (collectively, the “Existing Employment
Agreement”). 
 A. The Company desires to continue to employ the Executive to serve as its Chief Scientific
Officer, subject to the terms and conditions set forth in this Agreement, effective as of the Effective Date. 
 B. The
Executive desires to accept such continued employment by the Company, subject to the terms and conditions set forth in this Agreement, effective as of the Effective Date. 
 AGREEMENT 
 In consideration of the foregoing Recitals and the mutual
promises and covenants herein contained, and for other good and valuable consideration, the Parties, intending to be legally bound, agree as follows: 
 1. EMPLOYMENT. 
 1.1 Existing Employment Agreement. 

1.1.1 General. Effective as of the Effective Date, the Existing Employment Agreement shall be deemed terminated pursuant to
Section 4.4 thereof and superseded and replaced in its entirety by this Agreement and none of the parties thereto shall have any remaining rights or obligations thereunder, except as expressly provided in this Section 1.1. 

1.1.2 Bonus Payment Under Existing Employment Agreement. For purposes of the bonus payment that may have become payable pursuant
to Section 3.2 of the Existing Employment Agreement (the “Existing Bonus”), the Executive shall continue to be eligible to receive such Existing Bonus in accordance with the terms of the Existing Employment Agreement.

 1.1.3 Option Awards Under Existing Employment Agreement. For purposes of: (i) the Initial Option (as defined in
the Existing Employment Agreement) to purchase shares of the Company’s common stock (the “Common Stock”) granted to the Executive pursuant to the Stock Option Agreement, dated as of February 24, 2011 (the
“Initial 

 
Option Agreement”), by and between the Company and the Executive, the shares of Common Stock underlying such Initial Option shall continue to vest and become exercisable in
accordance with the terms of the Plan and the Initial Option Agreement; and (ii) the Subsequent Option (as defined in the Existing Employment Agreement and, together with the Initial Option, the “Existing Options”) to
purchase shares of Common Stock granted to the Executive pursuant to the Stock Option Agreement, dated as of October 31, 2011 (the “Subsequent Option Agreement” and, together with the Initial Option Agreement, the
“Existing Option Agreements”), by and between the Company and the Executive, the shares of Common Stock underlying the Subsequent Option (the “Subsequent Option Shares”) shall vest (x) as to fifty
percent (50%) of the Subsequent Option Shares, immediately as of the Effective Date and (y) as to the remaining Subsequent Option Shares, in equal monthly installments from January 1, 2013 through December 31, 2013 such that all
shares shall be vested as of December 31, 2013, subject to the Executive’s continued employment with the Company on each such vesting date; provided, however, that: (a) the Existing Options shall be subject to
accelerated vesting as provided in Section 3.4, Section 4.5.1, Section 4.5.2(ii) and Section 4.5.3(iii); and (b) “early exercise” of the Existing Options shall be permitted pursuant to the terms of the Plan and the
Existing Option Agreements. 
 1.2 Offer and Acceptance of Employment. The Company hereby agrees to continue to employ
the Executive, and the Executive hereby accepts such continued employment with the Company, in each case effective as of the Effective Date and otherwise subject to the terms and conditions set forth in this Agreement. 

1.3 Title. Effective as of the Effective Date, the Executive’s position shall be designated as Chief Scientific Officer,
subject to the terms and conditions set forth in this Agreement. 
 1.4 Term. The term of this Agreement shall begin on
the Effective Date and shall continue until terminated pursuant to Section 4 herein (the “Term”); provided, however, that the Parties expressly acknowledge and agree that the Executive’s employment
with the Company is at will and may, subject to the provisions of Section 4, be terminated by the Company or by the Executive at any time for any reason or for no reason. 
 1.5 Duties. During the Term, the Executive shall perform such services as are normally associated with the position of Chief Scientific Officer and shall report to the Company’s President and
Chief Executive Officer. The Executive shall also continue to serve as a member of the Board; provided, however, that the Executive shall not be entitled to any additional compensation for such service at any time when the Executive
remains employed by the Company pursuant to this Agreement. 
 1.6 Policies and Practices. The employment relationship
between the Parties shall be governed by this Agreement and by the policies and practices established by the Company and the Company’s board of directors (the “Board”). In the event that the terms of this Agreement
differ from or are in conflict with the Company’s policies or practices as in effect from time to time, this Agreement shall control. 

  
 2 

 1.7 Location. Unless the Parties otherwise agree in writing, during the Term the
Executive shall perform the services the Executive is required to perform pursuant to this Agreement at a business office established by the Company following the date of this Agreement that is located within fifty (50) miles of the
Executive’s residence on the Effective Date as set forth on the signature page hereto; provided, however, that the Company may from time to time require the Executive to travel temporarily to other locations (including Kansas
City) in connection with the Company’s business; and provided further that the Executive may elect in her sole discretion to perform the services the Executive is required to perform pursuant to this Agreement at any other
business office established by the Company (including in Kansas City). 
 2. DISCHARGE OF DUTIES; NONCOMPETITION. 

2.1 Duties. During the Executive’s employment by the Company, the Executive shall devote the substantial majority of the
Executive’s business time and sufficient time to the discharge of the Executive’s duties under this Agreement; provided, however, that, subject to Section 2.2 and Section 2.3 and provided that such activities do not
materially interfere with the performance of the Executive’s duties under this Agreement, the Executive may participate in the activities listed on Exhibit A attached hereto, as well as charitable, community or civic activities, and
any other activities that may be disclosed by the Executive in writing in advance to, and approved by, the Board after the date hereof; and provided further that, as of and following January 1, 2013, the Parties acknowledge and
agree that the time required to be spent by the Executive in connection with the performance of her duties under this Agreement shall be reduced in a manner appropriate to reflect the reduction of the Initial Base Salary (as defined below) to the
Continuing Base Salary (as defined below). 
 2.2 Covenant Not to Compete. The Executive acknowledges and agrees that the
business of the Company is nationwide in scope. The Executive further acknowledges and agrees that during the course of her employment with the Company she will learn confidential information relating to the Company and its business and business
strategies and will develop business relationships on behalf of the Company at the Company’s expense. The Executive acknowledges and agrees that if she were to divert this information and the relationships to a competitor, the Company would
suffer irreparable harm to its business and goodwill in an amount that cannot be readily quantified. Accordingly, the Executive agrees that during the Term and for twenty-four (24) months following the termination of her employment for any
reason, the Executive shall not engage in competition with the Company and/or any of its Affiliates (as defined below), either directly or indirectly, in any manner or capacity, as adviser, principal, agent, Affiliate, promoter, partner, officer,
director, employee, stockholder, owner, co- owner, consultant or member of any association or otherwise, in any phase of the business of developing, licensing, manufacturing, distributing or marketing of products or services that are in the same
field of use or which are otherwise in competition with the actual or reasonably anticipated products or services of the Company at the time of her separation from the Company, except with the prior written consent of the Board. The Executive
acknowledges and agrees that because of the nationwide scope of the Company’s business, this restriction shall be nationwide. For purposes of this Agreement, “Affiliate” means, with respect to any specific entity, any
other entity that, directly or indirectly, through one or more intermediaries, controls, is controlled by or is under common control with such specified entity. Ownership by the Executive in professionally managed funds over which the Executive does
not have control or discretion in 

  
 3 

 
investment decisions or as a passive investment of less than two percent (2%) of the outstanding shares of capital stock of any corporation with one or more classes of its capital stock
listed on a national securities exchange or publicly traded on a national securities exchange or in the over- the-counter market shall not constitute a breach of this Section 2.2. 

2.3 Covenant Not To Solicit. The Executive agrees that during the Term and for one (1) year following the termination of her
employment for any reason, she shall not, directly or indirectly, solicit or recruit any employees of the Company to terminate their work for the Company or to perform services in competition with the Company. 

3. COMPENSATION OF THE EXECUTIVE. 
 3.1 Base Salary. From the Effective Date through December 31, 2012, the Company shall pay the Executive a base salary at the rate of Two Hundred Seventy-Five Thousand U.S. Dollars
($275,000.00) per year (the “Initial Base Salary”), less payroll deductions and all required withholdings, payable in regular periodic payments in accordance with the Company’s normal payroll practices. Beginning on
January 1, 2013, the Company shall pay the Executive a base salary at the rate of Two Hundred Twenty-Five Thousand U.S. Dollars ($225,000.00) per year (the “Continuing Base Salary”), less payroll deductions and all
required withholdings, payable in regular periodic payments in accordance with the Company’s normal payroll practices. Each of the Initial Base Salary and the Continuing Base Salary shall be prorated for any partial year of employment on the
basis of a 365-day fiscal year and shall be subject to review and adjustment from time to time by and at the sole discretion of the Board (excluding the Executive) or any committee thereof. The Initial Base Salary or the Continuing Base Salary, as
in effect from time to time as applicable, is sometimes referred to herein as the “Base Salary”. 

3.2 Bonuses. 
 3.2.1 Annual Bonus. Beginning on January 1, 2013, the Executive will be eligible to receive an annual cash bonus (the “Bonus”) payment of up to twenty percent
(20%) of the Base Salary with respect to each calendar year, subject to the Executive’s continued employment with the Company as of the end of such calendar year and contingent upon successful achievement of corporate objectives
established from year to year by the Board (excluding the Executive). Any Bonus pursuant to this Section 3.2 shall be paid as promptly as practicable following the end of the applicable calendar year, but not later than March 15th of the
following calendar year. In addition to the foregoing, the Executive will be eligible to receive each year an additional cash bonus as determined in the sole discretion of the Board (excluding the Executive). 

3.2.2 Special Bonus. Promptly following the Effective Date, the Company shall pay the Executive a one-time cash bonus in the
amount of One Hundred Forty- Two Thousand Five Hundred Dollars ($142,500.00). 
 3.3 Restricted Stock Award. Subject to
Board approval (excluding the Executive), promptly following the Effective Date, the Company shall grant the Executive, without payment of additional consideration by the Executive, an award of 25,000 shares of restricted stock

  
 4 

 
(the “Restricted Stock Award”) pursuant to the Company’s 2010 Equity Incentive Plan (the “Plan”). The Restricted Stock Award shall be granted
subject to the terms and conditions of the Plan and a written award agreement to be entered into by the Company and the Executive (the “Restricted Stock Award Agreement”). The Restricted Stock Award Agreement shall provide,
among other things, that all shares of Common Stock underlying the Restricted Stock Award shall be fully vested as of the date of grant. 
 3.4 Acceleration Upon Change in Control. Upon the consummation by the Company of a Change in Control (as defined below), the vesting and exercisability of each of the Existing Options shall be
automatically accelerated in full. 
 3.5 Expense Reimbursements. The Company will reimburse the Executive for all
reasonable business expenses the Executive incurs in conducting her duties hereunder, pursuant to the Company’s usual expense reimbursement policies, provided that the Executive supplies the appropriate substantiation for such expenses. Any
amounts payable under this Section 3.5 shall be made in accordance with Treasury Regulation Section 1.409A-3(i)(1)(iv) and shall be paid on or before the last day of the Executive’s taxable year following the taxable year in which the
Executive incurred the expenses. The amounts provided under this Section 3.5 during any taxable year of the Executive’s will not affect such amounts provided in any other taxable year of the Executive’s, and the Executive’s right
to reimbursement for such amounts shall not be subject to liquidation or exchange for any other benefit. 
 3.6 Employment
Taxes. All of the Executive’s compensation shall be subject to all applicable federal, state and local taxes and withholdings, as well as any others that the Company determines it is legally required to withhold. 

3.7 Benefits; Vacation. The Executive shall, in accordance with Company policy and the terms of the applicable plan documents, be
eligible to participate in benefits under any benefit plan or arrangement that may be in effect from time to time and made available to the Company’s senior management employees, including with respect to additional coverage for spouses,
domestic partners and eligible dependents. In addition to the foregoing, the Executive shall be entitled to three (3) weeks’ paid vacation time per year, subject to a maximum accrual of three (3) weeks. 

4. TERMINATION. 
 4.1
Termination by the Company. The Executive’s employment with the Company is at will and may be terminated by the Company at any time and for any reason, or for no reason, including, but not limited to, under the following conditions:

 4.1.1 Termination by the Company for Cause. The Company may terminate the Executive’s employment under this
Agreement for Cause (as defined below) by delivery of written notice to the Executive specifying the Cause or Causes relied upon for such termination. Any notice of termination given pursuant to this Section 4.1.1 shall effect termination as of
the date of the notice, or as of such other date as specified in the notice. 
 4.1.2 Termination by the Company Without
Cause. The Company may terminate the Executive’s employment under this Agreement without Cause at any time and for 

  
 5 

 
any reason, or for no reason, by delivery of written notice to the Executive. Any notice of termination given pursuant to this Section 4.1.2 shall effect the termination of the
Executive’s employment hereunder as of the date of such notice, or as of such other date as is specified in such notice. 

4.2 Termination by the Executive. The Executive’s employment with the Company is at will and may be terminated by the
Executive at any time and for any reason, or for no reason, including, but not limited to, under the following conditions: 

4.2.1 Termination by the Executive for Good Reason. The Executive may terminate her employment under this Agreement for Good
Reason (as defined below) in accordance with the procedures specified in Section 4.6.2 below. 
 4.2.2 Termination by
the Executive Without Good Reason. The Executive may terminate her employment under this Agreement for other than Good Reason at any time. 
 4.3 Termination for Death or Complete Disability. The Executive’s employment with the Company shall automatically terminate effective upon the date of the Executive’s death or Complete
Disability (as defined below). 
 4.4 Termination by Mutual Agreement of the Parties. The Executive’s employment
with the Company may be terminated at any time upon a written mutual agreement of the Parties. Any such termination of employment shall have the consequences specified in such agreement. 

4.5 Compensation Upon Termination. 
 4.5.1 Death or Complete Disability. If the Executive’s employment shall be terminated by death or Complete Disability as provided in Section 4.3, the Company shall pay to the Executive,
or to the Executive’s heirs, as applicable, the Base Salary and accrued and unused vacation benefits earned through the date of termination at the rate in effect at the time of termination, plus all other amounts to which the Executive is
entitled under any compensation plan or practice of the Company at the time of termination, less standard deductions and withholdings. In addition, the vesting and/or exercisability of each of the Existing Options shall be automatically accelerated
on the date of termination as to the number of stock awards that would have vested over the twelve (12) month period following the date of termination had the Executive remained continuously employed by the Company during such period. The
Company shall thereafter have no further obligations to the Executive and/or to the Executive’s heirs under this Agreement, except as otherwise provided by law. 
 4.5.2 With Cause or Without Good Reason. 
 (i) If the
Executive’s employment is terminated by the Company for Cause, or if the Executive terminates her employment hereunder without Good Reason, the Company shall pay to the Executive the Base Salary and accrued and unused vacation benefits earned
through the date of termination at the rate in effect at the time of termination, plus all other amounts to which the Executive is entitled under any compensation plan or practice of the Company at the time of termination, less standard deductions
and withholdings. Subject to Section 4.5.2(ii), the Company shall thereafter have no further obligations to the Executive under this Agreement, except as otherwise provided by law. 

  
 6 

 (ii) In addition to the foregoing, if the Executive terminates her employment
hereunder without Good Reason on or following January 1, 2014, then, subject to the Executive’s: (i) furnishing to the Company an executed waiver and release of claims in substantially the form attached hereto as Exhibit B
(which form may be amended to comply with legal requirements arising after the Effective Date) (the “Release”) no later than forty-five (45) days following the Executive’s termination; and (ii) allowing the
Release to become effective in accordance with its terms, the Executive shall be entitled to the following: (x) continuation of the Base Salary in effect at the time of termination (but determined prior to any reduction in the Base Salary that
would give rise to the Executive’s right to voluntarily resign for Good Reason pursuant to Section 4.6.2), less standard deductions and withholdings, for a period of six (6) months following the date of termination, paid in equal
monthly installments over such six (6) month period pursuant to the Company’s standard payroll practices (the “Cash Severance”); and (y) the vesting and/or exercisability of each of the Existing Options shall
be automatically accelerated in full on the date of termination. 
 4.5.3 Without Cause or for Good Reason. If the
Company terminates the Executive’s employment without Cause or the Executive terminates her employment hereunder for Good Reason, the Company shall pay to the Executive the Base Salary and accrued and unused vacation benefits earned through the
date of termination at the rate in effect at the time of termination, plus all other amounts to which the Executive is entitled under any compensation plan or practice of the Company at the time of termination, less standard deductions and
withholdings. In addition, subject to the Executive’s: (i) furnishing to the Company an executed Release no later than forty-five (45) days following the Executive’s termination; and (ii) allowing the Release to become
effective in accordance with its terms, the Executive shall be entitled to the following: 
 (i) the Cash Severance;

 (ii) should the Executive elect to continue Company-sponsored group health insurance benefits in accordance with the
provisions of COBRA or State Continuation, as applicable, following the date of termination, to the extent that doing so will not result in adverse tax consequences or violate applicable law, the Company shall pay the full premium for such group
health insurance continuation benefits for the Executive and any eligible dependents for a period of six (6) months after the effective date of the Release; provided, however, that any such payments will cease if the Executive
voluntarily enrolls in a health insurance plan offered by another employer or entity during the period in which the Company is paying such premiums. The Executive agrees to promptly notify the Company in writing of any such enrollment. For purposes
of this Section 4.5.3(ii), references to COBRA or State Continuation premiums shall not include any amounts payable by the Executive under an Internal Revenue Code Section 125 health care reimbursement plan; and 

(iii) the vesting and/or exercisability of each of the Existing Options shall be automatically accelerated in full on the date of
termination. 

  
 7 

 4.6 Definitions. For purposes of this Agreement, the following terms shall have the
following meanings: 
 4.6.1 Complete Disability. “Complete Disability” shall mean the inability
of the Executive to perform the Executive’s duties under this Agreement, even with reasonable accommodation, because the Executive has become permanently disabled within the meaning of any policy of long-term disability income insurance
covering employees of the Company then in force. In the event the Company has no policy of disability income insurance covering employees of the Company in force when the Executive becomes disabled, the term “Complete Disability” shall
mean the inability of the Executive to perform the Executive’s duties under this Agreement, even with reasonable accommodation, by reason of any incapacity, physical or mental, which the Board, based upon medical advice or an opinion provided
by a licensed physician mutually acceptable to the Board and the Executive, determines to have incapacitated the Executive from satisfactorily performing all of the Executive’s usual services for the Company, even with reasonable accommodation,
for a period of at least one hundred twenty (120) days during any twelve (12) month period (whether or not consecutive). Based upon such medical advice or opinion, the determination of the Board shall be final and binding and the date such
determination is made shall be the date of such Complete Disability for purposes of this Agreement. 
 4.6.2 Good Reason.
“Good Reason” for the Executive to terminate her employment hereunder shall mean the occurrence of any of the following events without the Executive’s consent: 

(i) a material diminution in the Executive’s authority, duties or responsibilities relative to her authority, duties or
responsibilities in effect immediately prior to such reduction; 
 (ii) a material change in the geographic location at
which the Executive must perform her duties to a point that is located more than fifty (50) miles from the Executive’s residence as set forth on the signature page hereto or, in the event that the Executive elects to perform the services
required by this Agreement at any other business office established by the Company, a material change in the geographic location at which the Executive must perform her duties to a point that is located more than fifty (50) miles from such
business office; 
 (iii) a material diminution by the Company of the Executive’s base compensation as initially
set forth herein or as the same may be increased from time to time; or 
 (iv) any other action or inaction that
constitutes a material breach by the Company or any successor or Affiliate of its obligations to the Executive under this Agreement; provided, however, that such termination by the Executive shall only be deemed for Good Reason
pursuant to the foregoing definition if: (x) the Executive gives the Company written notice of the intent to terminate for Good Reason within thirty (30) days following the first occurrence of the condition(s) that the Executive believes
constitutes Good Reason, which notice shall describe such condition(s); (y) the Company fails to remedy such condition(s) within thirty (30) days following receipt of the written notice (the “Cure Period”); and
(z) the Executive terminates her employment within thirty (30) days following the end of the Cure Period. 

  
 8 

 4.6.3 Cause. “Cause” for the Company to terminate the
Executive’s employment hereunder shall mean the occurrence of any of the following events, as determined by the Board or a committee designated by the Board, in its sole discretion: 

(i) the Executive’s conviction of any felony or any crime involving moral turpitude or dishonesty; 

(ii) the Executive’s participation in a fraud involving or against the Company; 

(iii) the Executive’s willful and material breach of the Executive’s duties hereunder that is not cured within thirty
(30) days after the Executive’s receipt of written notice from the Board of such breach; 
 (iv) the
Executive’s intentional and material damage to the Company’s property; or 
 (v) the Executive’s material
breach of the Non-Disclosure and Assignment Agreement (as defined below); 
 provided, however, that prior to the determination
that Cause under this Section 4.6.3 has occurred, the Company shall: (w) provide to the Executive in writing, in reasonable detail, the reasons for the determination that such Cause exists; (x) other than with respect to
clause (iii) above which specifies the applicable period of time for the Executive to remedy her breach, afford the Executive a reasonable opportunity to remedy any such breach; (y) provide the Executive an opportunity to be heard prior to
the final decision to terminate the Executive’s employment hereunder for such Cause; and (z) make any decision that such Cause exists in good faith. 
 4.6.4 Change in Control. “Change in Control” shall mean the occurrence, in a single transaction or in a series of related transactions, of any one or more of the following
events: (i) there is consummated a merger, consolidation or similar transaction involving (directly or indirectly) the Company if, immediately after the consummation of such merger, consolidation or similar transaction, the stockholders of the
Company immediately prior thereto do not own, directly or indirectly, either (a) outstanding voting securities representing more than fifty percent (50%) of the combined outstanding voting power of the surviving entity in such merger,
consolidation or similar transaction or (b) more than fifty percent (50%) of the combined outstanding voting power of the parent of the surviving entity in such merger, consolidation or similar transaction; (ii) the stockholders of
the Company approve or the Board approves a plan of complete dissolution or liquidation of the Company, or a complete dissolution or liquidation of the Company shall otherwise occur; or (iii) there is consummated a sale of all or substantially
all of the consolidated assets of the Company and its subsidiaries, other than a sale of all or substantially all of the consolidated assets of the Company and its subsidiaries to an entity more than fifty percent (50%) of the combined voting
power of the voting securities of which entity is owned by stockholders of the Company in substantially the same proportion as 

  
 9 

 
their ownership of the Company immediately prior to such sale; provided, however, that the term “Change in Control” shall not include a sale of assets, merger or other
transaction effected exclusively for the purpose of changing the domicile of the Company. 
 4.7 Survival of Certain
Sections. Sections 2.2, 2.3, 4, 5, 6, 7, 8, 9, 12, 13, 16 and 18 of this Agreement will survive the termination of this Agreement. 
 4.8 Parachute Payment. If any payment or benefit the Executive would receive pursuant to this Agreement (each, a “Payment”) would: (i) constitute a
“Parachute Payment” within the meaning of Section 280G of the Internal Revenue Code of 1986, as amended (the “Code”); and (ii) but for this sentence, be subject to the excise tax imposed by
Section 4999 of the Code (the “Excise Tax”), then such Payment shall be reduced to the Reduced Amount. The “Reduced Amount” shall be equal to the largest portion of the Payment (including all of
it) which, after taking into account all applicable federal, state and local income and employment taxes (all computed at the highest applicable marginal rate), and the Excise Tax, if applicable, results in the Executive’s receipt, on an
after-tax basis, of the greatest amount of the Payment, whether or not all or some portion of the Payment is subject to the Excise Tax. If a reduction in payments or benefits constituting Parachute Payments is necessary so that the Payment equals
the Reduced Amount, reduction shall occur in the following order unless the Executive elects in writing a different order (provided, however, that such election shall be subject to Company approval if made on or after the effective
date of the event that triggers the Payment): reduction of cash payments; cancellation of accelerated vesting of stock awards; reduction of employee benefits. In the event that acceleration of vesting of stock award compensation is to be reduced,
such acceleration of vesting shall be cancelled in the reverse order of the date of grant of the Executive’s stock awards unless the Executive elects in writing a different order for cancellation. Notwithstanding anything to the contrary set
forth herein, the Executive may not elect the order in which the reduction in the Executive’s payments or benefits will occur if such election would cause any such amounts to constitute “nonqualified deferred compensation” within the
meaning of Section 409A of the Code such that the Executive would incur the additional twenty percent (20%) tax under Section 409A of the Code (the “409A Tax”). In addition, if a different order of reduction is
required to avoid the 409A Tax, that order shall apply. 
 The accounting firm then engaged by the Company for general audit
purposes shall perform the foregoing calculations. The Company shall bear all expenses with respect to the determinations by such accounting firm required to be made hereunder. 

The accounting firm engaged to make the determinations hereunder shall provide its calculations, together with detailed supporting
documentation, to the Executive and the Company within fifteen (15) calendar days after the date on which the Executive’s right to a Payment is triggered (if requested at that time by the Executive or the Company) or such other time as
requested by the Executive or the Company. If the accounting firm determines that no Excise Tax is payable with respect to a Payment, either before or after the application of the Reduced Amount, it shall furnish the Executive and the Company with
an opinion reasonably acceptable to the Executive that no Excise Tax will be imposed with respect to such Payment. Any good faith determinations of the accounting firm made hereunder shall be final, binding and conclusive upon the Executive and the
Company. 

  
 10 

 4.9 Application of Internal Revenue Code Section 409A. Notwithstanding anything
to the contrary set forth herein, any Cash Severance amounts that constitute “nonqualified deferred compensation” within the meaning of Section 409A of the Code shall not commence in connection with the Executive’s termination of
employment unless and until the Executive has also incurred a “separation from service” within the meaning of Section 409A of the Code, unless the Company reasonably determines that such amounts may be provided to the Executive
without causing the Executive to incur the 409A Tax. To the extent any Cash Severance amounts: (i) are paid following the date of termination of the Executive’s employment through March 15 of the calendar year following such
termination, such severance benefits are intended to constitute separate payments for purposes of Section 1.409A-2(b)(2) of the Treasury Regulations and thus payable pursuant to the “short-term deferral” rule set forth in
Section 1.409A-1(b)(4) of the Treasury Regulations; (ii) are paid following said March 15, such Cash Severance benefits are intended to constitute separate payments for purposes of Section 1.409A-2(b)(2) of the Treasury
Regulations made upon an involuntary separation from service and payable pursuant to Section 1.409A-1(b)(9)(iii) of the Treasury Regulations, to the maximum extent permitted by said provision; and (iii) are in excess of the amounts
specified in clauses (i) and (ii) of this paragraph, shall (unless otherwise exempt under Treasury Regulations) be considered separate payments subject to the distribution requirements of Section 409A(a)(2)(A) of the Code, including,
without limitation, the requirement of Section 409A(a)(2)(B)(i) of the Code that payments or benefits be delayed until six (6) months and one (1) day after the Executive’s separation from service if the Executive is a
“specified employee” within the meaning of the aforesaid section of the Code at the time of such separation from service. In the event that a six (6) month and one (1) day delay of any such separation payments or benefits is
required, on the first regularly scheduled pay date following the conclusion of the delay period the Executive shall receive a lump sum payment or benefit in an amount equal to the separation payments and benefits that were so delayed, and any
remaining separation payments or benefits shall be paid on the same basis and at the same time as otherwise specified pursuant to this Agreement (subject to applicable tax withholdings and deductions). 

5. CONFIDENTIAL AND PROPRIETARY INFORMATION. As a condition of employment, the Executive agrees to execute and abide by the Company’s
standard form of Non-Disclosure and Proprietary Rights Assignment Agreement (the “Non-Disclosure and Assignment Agreement”). 

6. ASSIGNMENT AND BINDING EFFECT. This Agreement shall be binding upon and inure to the benefit of the Executive and the Executive’s heirs,
executors, personal representatives, assigns, administrators and legal representatives. Because of the unique and personal nature of the Executive’s duties under this Agreement, neither this Agreement nor any rights or obligations under this
Agreement shall be assignable by the Executive. This Agreement shall be binding upon and inure to the benefit of the Company and its successors, assigns and legal representatives. Any such successor of the Company will be deemed substituted for the
Company under the terms of this Agreement for all purposes and the Company will require any successor to all or substantially all of the business or assets of the Company expressly to assume and to agree to perform this Agreement in the same manner
and to the same extent that the Company would be required to perform it if no such succession had taken place. For this purpose, “successor” means any person, firm, corporation or other business entity which at any time, whether by
purchase, merger or otherwise, directly or indirectly acquires all or substantially all of the assets or business of the Company. 

  
 11 

 7. NOTICES. All notices or demands of any kind required or permitted to be given by the Company or
the Executive under this Agreement shall be given in writing and shall be personally delivered (and receipted for) or faxed during normal business hours or mailed by certified mail, return receipt requested, postage prepaid, addressed as follows:

 If to the Company: 
 Aratana Therapeutics, Inc. 
 1901 Olathe Boulevard 

Kansas City, KS 66103 
 Attention: Chairman of the Board 
 If to the Executive, to the address set forth
on the signature page hereto. 
 Any such written notice shall be deemed given on the earlier of the date on which such notice is personally
delivered or three (3) days after its deposit in the United States mail as specified above. Either Party may change its address for notices by giving notice to the other Party in the manner specified in this section. 

8. CHOICE OF LAW. This Agreement shall be construed and interpreted in accordance with the internal laws of the State of Delaware. The Executive
and the Company consent to non-exclusive personal jurisdiction in any state and, if otherwise permitted by law, federal court situated in the State of Delaware for the resolution of all claims arising under this Agreement that are subject to
resolution in court rather than through arbitration. 
 9. INTEGRATION. This Agreement, including the exhibits hereto, together with the
Non-Disclosure and Assignment Agreement, contains the complete, final and exclusive agreement of the Parties relating to the terms and conditions of the Executive’s employment and the termination of the Executive’s employment, and
supersedes all prior oral and written employment agreements or arrangements between the Parties. 
 10. AMENDMENT. This Agreement cannot
be amended or modified except by a written agreement signed by the Executive and the Company. 
 11. WAIVER. No term, covenant or
condition of this Agreement or any breach thereof shall be deemed waived, except with the written consent of the Party against whom the wavier is claimed, and any waiver or any such term, covenant, condition or breach shall not be deemed to be a
waiver of any preceding or succeeding breach of the same or any other term, covenant, condition or breach. 
 12. SEVERABILITY. The
finding by a court of competent jurisdiction of the unenforceability, invalidity or illegality of any provision of this Agreement shall not render any other provision of this Agreement unenforceable, invalid or illegal. Such court shall have the
authority to modify or replace the invalid or unenforceable term or provision with a valid and enforceable term or provision, which most accurately represents the Parties’ intention with respect to the invalid or unenforceable term, or
provision. 

  
 12 

 13. INTERPRETATION; CONSTRUCTION. The headings set forth in this Agreement are for convenience of
reference only and shall not be used in interpreting this Agreement. This Agreement has been drafted by legal counsel representing the Company, but the Executive has been encouraged to consult with, and has consulted with, the Executive’s own
independent counsel and tax advisors with respect to the terms of this Agreement. The Parties acknowledge that each Party and its counsel has reviewed and revised, or had an opportunity to review and revise, this Agreement, and any rule of
construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of this Agreement. 
 14. REPRESENTATIONS AND WARRANTIES. The Executive represents and warrants that the Executive is not restricted or prohibited, contractually or otherwise, from entering into and performing each of
the terms and covenants contained in this Agreement, and that the Executive’s execution and performance of this Agreement will not violate or breach any other agreements between the Executive and any other person or entity. 

15. COUNTERPARTS. This Agreement may be executed in two (2) counterparts, each of which shall be deemed an original, all of which together
shall constitute one and the same instrument. 
 16. ARBITRATION. To ensure the rapid and economical resolution of disputes that may
arise in connection with the Executive’s employment with the Company, the Executive and the Company agree that any and all disputes, claims, or causes of action, in law or equity, arising from or relating to the Executive’s employment, or
the termination of that employment, will be resolved, to the fullest extent permitted by law, by final, binding and confidential arbitration pursuant to the Federal Arbitration Act in Kansas City, Kansas conducted by the Judicial Arbitration and
Mediation Services/Endispute, Inc. (“JAMS”), or its successors, under the then current rules of JAMS for employment disputes; provided that the arbitrator shall: (a) have the authority to compel adequate discovery
for the resolution of the dispute and to award such relief as would otherwise be permitted by law; and (b) issue a written arbitration decision including the arbitrator’s essential findings and conclusions and a statement of the award.
ACCORDINGLY, THE EXECUTIVE AND THE COMPANY HEREBY IRREVOCABLY WAIVE ANY RIGHT TO A JURY TRIAL IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT. Both the Executive and the Company shall be entitled to all rights and remedies that
either the Executive or the Company would be entitled to pursue in a court of law. The Company shall pay any JAMS filing fee and shall pay the arbitrator’s fee. The arbitrator shall have the discretion to award attorneys’ fees to the party
the arbitrator determines is the prevailing party in the arbitration; provided, however, that the prevailing party shall be reimbursed for such fees, costs and expenses within sixty (60) days following any such award, but, to the
extent the Executive is the prevailing party, in no event later than the last day of the Executive’s taxable year following the taxable year in which the fees, costs and expenses were incurred; provided, further, that the
Parties’ obligations pursuant to the provisos set forth above shall terminate on the tenth (10th) anniversary of the date of the Executive’s termination of employment. Nothing in this Agreement is intended to prevent either the
Executive or the Company from obtaining equitable relief in court to prevent irreparable harm pending the 

  
 13 

 
conclusion of any such arbitration. Notwithstanding the foregoing, the Executive and the Company each have the right to resolve any issue or dispute involving a claim of misappropriation or
infringement of confidential, proprietary or trade secret information, or intellectual property rights, in any court of competent jurisdiction instead of via arbitration. 
 17. TRADE SECRETS OF OTHERS. It is the understanding and intention of both the Company and the Executive that the Executive shall not divulge to the Company and/or its subsidiaries any confidential
information or trade secrets belonging to others, including the Executive’s former employers, nor shall the Company and/or its Affiliates seek to elicit from the Executive any such information. The Executive shall not provide to the Company
and/or its Affiliates or use on their behalf any such information or any documents or copies of documents containing such information. 
 18.
ADVERTISING WAIVER. The Executive agrees to permit, during and following the term of this Agreement, and without receiving additional compensation, the Company, and persons or other organizations authorized by the Company, to use, publish and
distribute advertising or sales promotional literature concerning the products and/or services of the Company, or the machinery and equipment used in the provision thereof, in which the Executive’s name and/or pictures of the Executive taken in
the course of the Executive’s provision of services to the Company appear. The Executive hereby waives and releases any claim or right the Executive may otherwise have arising out of such use, publication or distribution. 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  
 14 

 IN WITNESS WHEREOF, the Parties have executed this Agreement as of the date first
written above. 
  

			
	ARATANA THERAPEUTICS, INC.
	
	 /s/ Steven St. Peter

	By:	 	Steven St. Peter
	Its:	 	President
		
	Dated:	 	9/26/2012

			
	
	EXECUTIVE:
	
	 Linda Rhodes

	LINDA RHODES
		
	Dated:	 	26 September 2012
		
	Address:	 	3 White Birch Lane
		 	Holmdel, NJ 07733

 [SIGNATURE PAGE TO EMPLOYMENT AGREEMENT] 

 EXHIBIT A 

PERMITTED ACTIVITIES 
  

	1)	Teaching in the Rutgers Graduate School of Animal Science Adjunct faculty member 

 

	 	•	 	 One semester course on Animal Pharmaceutical Development 

 

	 	•	 	 Occasional seminars 

  

	2)	Board of Managers of the New Jersey Agricultural Extension Service 

  

	 	•	 	 Four evening meetings a year in NJ – a few hours each. 

 

	 	•	 	 Oversight of a variety of activities at Rutgers and in NJ involved in agricultural research and support; an “outside” member representing
Biotechnology on the Board. 

  

	3)	ImmuCell Board of Directors 

  

	 	•	 	 Four meetings per year, two teleconferences, two in person, Portland, ME 

 

	 	•	 	 (ImmuCell is a small public company located in Portland, ME marketing products to the dairy and beef producers, and developing a novel mastitis
treatment through FDA approval.) 

  

	4)	Found Animal Foundation Scientific Advisory Board ad hoc Member 

  

	 	•	 	 One to four 1 day meetings per year, in person in Santa Monica, CA 

 

	 	•	 	 Occasional grant review of the Michaelson Grant program 

 

	 	•	 	 Purpose to review grants on dog and cat non-surgical contraception/sterilization as part of the Michelson Prize and Grants program

  

	5)	Alliance for Contraception in Cats and Dogs Board Member 

  

	 	•	 	 Six meeting per year, 5 teleconferences, 1 in person (different locales) 

 

	 	•	 	 Assistance throughout the year on technical questions, fund raising 

 

	 	•	 	 ACC&D is an organization to promote the development of non-surgical sterilants/contraceptive s for companion animals. 

 

	6)	University of Pennsylvania Veterinary Medical Alumni Society Executive Board Member 

 

	 	•	 	 Four to five half-day meetings a year in Philadelphia; purpose to support fund- raising and alumni contact with UPenn Vet School.

 EXHIBIT B 
 RELEASE AND WAIVER OF CLAIMS 
 In consideration of the payments and other
benefits set forth in the Employment Agreement dated September 6, 2012 (the “Employment Agreement”), to which this form is attached, I, Linda Rhodes, hereby furnish ARATANA THERAPEUTICS , INC. (the
“Company”), with the following release and waiver (“Release and Waiver”). 
 In
exchange for the consideration provided to me by Section 4 of the Employment Agreement that I am not otherwise entitled to receive, I hereby generally and completely release the Company and its directors, officers, employees, shareholders,
partners, agents, attorneys, predecessors, successors, parent and subsidiary entities, insurers, Affiliates, and assigns from any and all claims, liabilities and obligations, both known and unknown, that arise out of or are in any way related to
events, acts, conduct, or omissions occurring prior to my signing this Release and Waiver, except claims that the law does not permit me to waive by signing this Release and Waiver. This general release includes, but is not limited to: (1) all
claims arising out of or in any way related to my employment with the Company or the termination of that employment; (2) all claims related to my compensation or benefits from the Company, including salary, bonuses, commissions, vacation pay,
expense reimbursements, severance pay, fringe benefits, stock, stock options, or any other ownership interests in the Company; (3) all claims for breach of contract, wrongful termination, and breach of the implied covenant of good faith and
fair dealing; (4) all tort claims, including claims for fraud, defamation, emotional distress, and discharge in violation of public policy; and (5) all federal, state, and local statutory claims, including claims for discrimination,
harassment, retaliation, attorneys’ fees, or other claims arising under the federal Civil Rights Act of 1964 (as amended), the federal Americans with Disabilities Act of 1990, the federal Age Discrimination in Employment Act of 1967 (as
amended) (“ADEA”), the Kansas Anti-discrimination Act and the Kansas Age Discrimination in Employment Act. 
 Notwithstanding the foregoing, nothing in this Release and Waiver shall constitute a release by me of any claims or damages based on any right I may have to enforce the Company’s executory
obligations under the Employment Agreement, or my eligibility for indemnification under applicable law, Company governance documents, my indemnification agreement with the Company or under any applicable insurance policy with respect to my liability
as an employee or officer of the Company, or my rights pursuant to my stock awards (including any stock options, restricted stock or other awards granted to me by the Company) pursuant to their terms. 

I acknowledge that, among other rights, I am waiving and releasing any rights I may have under ADEA, that this Release and Waiver is
knowing and voluntary, and that the consideration given for this Release and Waiver is in addition to anything of value to which I was already entitled as an executive of the Company. If I am 40 years of age or older upon execution of this Release
and Waiver, I further acknowledge that I have been advised, as required by the Older Workers Benefit Protection Act, that: (a) the release and waiver granted herein does not relate to claims under the ADEA which may arise after this Release and
Waiver is executed; (b) I should consult with an attorney prior to executing this Release and Waiver; (c) I have twenty-one (21) days from the date of termination of my employment with the Company in which to consider this Release and
Waiver (although I may choose voluntarily to execute this Release and 

 
Waiver earlier); (d) I have seven (7) days following the execution of this Release and Waiver to revoke my consent to this Release and Waiver; and (e) this Release and Waiver shall
not be effective until the seven (7) day revocation period has expired. 
 I acknowledge my continuing obligations under my
Non-Disclosure and Assignment Agreement. Pursuant to the Non-Disclosure and Assignment Agreement I understand that among other things, I must not use or disclose any confidential or proprietary information of the Company and I must promptly return
all Company property and documents (including all embodiments of proprietary information) and all copies thereof in my possession or control. I understand and agree that my right to the severance pay I am receiving in exchange for my agreement to
the terms of this Release and Waiver is contingent upon my continued compliance with my Non-Disclosure and Assignment Agreement. 
 This Release and Waiver constitutes the complete, final and exclusive embodiment of the entire agreement between the Company and me with regard to the subject matter hereof. I am not relying on any
promise or representation by the Company that is not expressly stated herein. This Release and Waiver may only be modified by a writing signed by both me and a duly authorized officer of the Company. 

 

									
	Date:	 	  
	 		 	By:	 	  

					
		 		 		 	Name:	 	  

 ARATANA THERAPEUTICS, INC. 

AMENDMENT NO. 1 TO 
 EMPLOYMENT AGREEMENT 
 THIS AMENDMENT
NO. 1 TO EMPLOYMENT AGREEMENT (this “Amendment”) is made and entered into as of April 29, 2013, by and between ARATANA
THERAPEUTICS, INC., a Delaware corporation (the “Company”), and Linda Rhodes (the “Executive”). Capitalized terms used and not otherwise defined herein shall have the
meanings given to them in the Original Agreement (as defined below). 
 RECITALS 

WHEREAS, the Company and the Executive are parties to that certain Employment Agreement, dated as of
September 6, 2012 (the “Original Agreement”); and 
 WHEREAS, in accordance
with Section 10 of the Original Agreement, the Company and the Executive desire to amend the Original Agreement as set forth in this Amendment. 
 NOW, THEREFORE, in consideration of the mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of
which are hereby acknowledged, the parties agree as follows: 
 AMENDMENT 

1. AMENDMENTS TO ORIGINAL AGREEMENT. 

1.1 Amendment to Section 3.2.1. Section 3.2.1 of the Original Agreement is hereby amended and restated in its entirety to
read as follows: 
 “3.2.1 Annual Bonus. Beginning on January 1, 2013, the Executive will be
eligible to receive an annual cash bonus (the “Bonus”) payment of up to thirty percent (30%) of the Base Salary with respect to each calendar year, subject to the Executive’s continued employment with the Company as
of the end of such calendar year and contingent upon successful achievement of corporate objectives established from year to year by the Board (excluding the Executive). Any Bonus pursuant to this Section 3.2 shall be paid as promptly as
practicable following the end of the applicable calendar year, but not later than March 15th of the following calendar year. In addition to the foregoing, the Executive will be eligible to receive each year an additional cash bonus as
determined in the sole discretion of the Board (excluding the Executive).” 
 1.2 Amendment to Section 3.3.
Section 3.3 of the Original Agreement is hereby retitled “Equity Compensation,” existing Section 3.3 (entitled “Restricted Stock Award”) is hereby renumbered as Section 3.3.1, and the following
Section 3.3.2 is hereby added to Section 3.3 following renumbered Section 3.3.1: 

 “3.3.2 IPO Stock Option. 

(i) On the date the Company’s registration statement relating to its initial public offering becomes effective (the
“IPO Effective Date”), the Company shall grant the Executive a stock option (the “IPO Stock Option”) pursuant to the Company’s 2013 Incentive Award Plan or such other equity incentive plan or
similar plan in effect on the IPO Effective Date (the “New Plan”) to purchase 25,000 shares of Common Stock (adjusted for any stock splits, reverse stock splits or other changes affecting the shares of Common Stock that may
occur prior to the date of grant), at a per share exercise price equal to the fair market value of a share of Common Stock on the date of grant. 
 (ii) The IPO Stock Option shall be granted subject to the terms and conditions of the New Plan and a written option agreement to be entered into by the Company and the Executive (the “IPO
Option Agreement”). The IPO Option Agreement shall provide, among other things, that the shares of Common Stock underlying the IPO Stock Option (the “IPO Option Shares”) shall vest: (x) as to 1/4th of the
IPO Option Shares, upon the first (1st) anniversary of the date of grant of the IPO Stock Option; and (y) as to the remaining IPO Option Shares, in equal monthly installments over the next thirty-six (36) months such that all shares
shall be vested as of the fourth (4th) anniversary of the date of grant of the IPO Stock Option, subject to the Executive’s continued employment with the Company on each such vesting date; provided, however, that:
(a) the IPO Stock Option shall be subject to accelerated vesting as provided in Section 4.5.1 and Section 4.5.3(iii); and (b) “early exercise” of the IPO Stock Option shall be permitted pursuant to the terms of the New
Plan and the IPO Option Agreement.” 
 1.3 Amendment to Section 4.5.3. Subparagraphs (i), (ii) and
(iii) of Section 4.5.3 of the Original Agreement are hereby amended and restated in their entirety to read as follows: 
 “(i) payment in an amount equal to fifty percent (50%) of the Executive’s annual Base Salary in effect at the time of termination (or 100% of the Executive’s Base Salary in effect at
the time of termination, in the event the termination occurs on account of or within twelve (12) months following the date of the consummation of a Change in Control (as defined below) (such period, the “Double-Trigger
Period”)) (with the amount of the Base Salary determined prior to any reduction in the Base Salary that would give rise to the Executive’s right to voluntarily resign for Good Reason pursuant to Section 4.6.2), less standard
deductions and withholdings, paid in equal installments over a period of six (6) months (or twelve (12) months, in the event the termination occurs during the Double-Trigger Period) pursuant to the Company’s standard payroll practices
(for the avoidance of doubt and notwithstanding the definition of “Cash Severance” in Section 4.5.2(ii), if the Executive is entitled to payments under this Section 4.5.3, “Cash Severance”
for purposes of this Agreement shall refer to payments made pursuant to this subparagraph (i)); 

  
 2 

 (ii) should the Executive elect to continue Company-sponsored group health
insurance benefits in accordance with the provisions of COBRA or State Continuation, as applicable, following the date of termination, to the extent that doing so will not result in adverse tax consequences or violate applicable law, the Company
shall pay the full premium for such group health insurance continuation benefits for the Executive and any eligible dependents for a period of six (6) months (or twelve (12) months, in the event the termination occurs during the
Double-Trigger Period) after the effective date of the Release; provided, however, that any such payments will cease if the Executive voluntarily enrolls in a health insurance plan offered by another employer or entity during the
period in which the Company is paying such premiums. The Executive agrees to promptly notify the Company in writing of any such enrollment. For purposes of this Section 4.5.3(ii), references to COBRA or State Continuation premiums shall not
include any amounts payable by the Executive under an Internal Revenue Code Section 125 health care reimbursement plan; and 
 (iii) the vesting and/or exercisability of each of the Executive’s Existing Options shall be accelerated in full on the effective date of the Release, and the vesting and/or exercisability of each of
the Executive’s New Awards shall be automatically accelerated on the effective date of the Release as to the number of stock awards that would have vested over the six (6) month period following the date of termination had the Executive
remained continuously employed by the Company during such period; provided, however, that in the event that the termination occurs during the Double-Trigger Period, the vesting and exercisability of each of the Executive’s
outstanding New Awards shall be automatically accelerated in full, which shall mean at target for any portion of the New Awards that vests based on the achievement of performance goals.” 

1.4 Amendment to Section 4.6. Section 4.6 of the Original Agreement is hereby amended by adding the following
definition: 
 “4.6.5 New Awards. “New Awards” shall mean the IPO Stock
Option and any other stock options, restricted stock or other equity awards granted to the Executive by the Company, with the exception of the Existing Options. 

  
 3 

 2. MISCELLANEOUS 

2.1 Effective Date. This Amendment shall become effective on the IPO Effective Date, if and only if the following conditions (the
“Conditions”) are satisfied: (i) the Executive is still employed by the Company on the IPO Effective Date, and (ii) the IPO Effective Date is no later than September 30, 2013. For the avoidance of doubt, if
either of the Conditions is not satisfied, this Amendment shall be of no force or effect and shall not become effective. 

2.2 No Other Amendment. Except as specifically amended by this Amendment, the terms and conditions of the Original Agreement shall
remain unchanged and in full force and effect. 
 2.3 Counterparts; Execution by Facsimile. This Amendment may be
executed in any number of counterparts, each of which shall be deemed an original and all of which together shall constitute one and the same instrument. The exchange of copies of this Amendment and of signature pages thereto by facsimile
transmission or by e-mail transmission in portable digital format, or similar format, shall constitute effective execution and delivery of such instrument(s) by the parties and may be used in lieu of the original Amendment for all purposes.

 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  
 4 

 IN WITNESS WHEREOF, the
parties have duly executed and delivered this AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT as of the date first written above. 

COMPANY: 
  

			
	ARATANA THERAPEUTICS, INC.
		
	By:	 	/s/ Steven St. Peter
	 Name: Steven St. Peter
 Its:       President and CEO

			
		
	Dated: 	 	4/29/2013

 EXECUTIVE: 

	
	
	/s/ Linda Rhodes

 LINDA RHODES 

			
		
	Dated: 	 	4/29/2013

 [SIGNATURE PAGE TO AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00217-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00217-of-00352.parquet"}]]